Coca-Cola's strong Q3 results and its move to sell a majority stake in its African bottling operations highlight the company's resilience and growth potential.
US obesity declines as GLP-1 drug use rises, with potential benefits beyond weight loss.
Coca-Cola's strong Q3 results and its move to sell a majority stake in its African bottling operations highlight the company's resilience and growth potential.
US obesity declines as GLP-1 drug use rises, with potential benefits beyond weight loss.
